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PURPOSE. Neurofibromatosis type 1 (NF1) is a monogenic dis-
order with the majority of patients presenting subtle to mod-
erate cognitive impairments. Visuospatial deficits are consid-
ered to be one of the hallmark characteristics of their cognitive
profile. However, low-level visual processing has not been
previously investigated. Our aim was to study contrast percep-
tion in these patients to assess the function of early visual areas.
METHODS. Contrast sensitivity was tested in 19 children and
adolescents with NF1 and 33 control children and adolescents
and 12 adults with NF1 and 24 control adults. The tasks used
probed two achromatic spatiotemporal frequency channels
and chromatic red–green and blue–yellow pathways.
RESULTS. Individuals with NF1 showed significant contrast sen-
sitivity deficits for the achromatic higher spatial frequency
channel [F(1,83)  36.1, P  0.001] and for the achromatic low
spatial high temporal (magnocellular) frequency channel
[F(1,72)  8.0, P  0.01]. Furthermore, individuals with NF1
presented a significant deficit in chromatic red–green (parvo-
cellular) contrast sensitivity (P  0.01) but not in blue–yellow
(koniocelular) sensitivity. The decrease in achromatic sensitiv-
ity for higher spatial frequency was observed throughout the
visual field, in both central and peripheral locations. In con-
trast, central contrast sensitivity for the magnocellular-biased
condition was relatively preserved and only peripheral sensi-
tivity was affected. Interestingly, the same pattern of deficits
was found in both age groups tested.
CONCLUSIONS. These findings showed that contrast sensitivity is
impaired in patients with NF1, associating for the first time
abnormal low-level vision to the cognitive profile of this
disorder. (Invest Ophthalmol Vis Sci. 2012;53:287–293) DOI:
10.1167/iovs.11-8225
Neurofibromatosis type 1 (NF1) is a monogenic disorderwith an incidence of around 1:3500.1 A high percentage
of patients with NF1 show cognitive deficits.2 In particular,
visuospatial deficits are considered to be one of the hallmark
characteristics of their cognitive profile.3,4 In addition, individ-
uals with NF1 underperform in receptive and expressive lan-
guage assessments, tests of executive function, global atten-
tion, motor speed, and coordination.3,5,6 Children with NF1
are also more likely to develop attention-deficit hyperactivity
disorder, present in 30 to 50% of patients.3 The origin and
extent of these problems is not fully understood.3 One possi-
bility is that deficits in low-level vision are present and may
underlie, at least in part, the NF1 cognitive problems. Indeed,
one functional magnetic resonance imaging study revealed
decreased activation of the occipital visual cortex of these
patients.7 Yet, low-level vision has not been studied before in
NF1.
In early stages of visual processing, information is transmit-
ted from the retina to the visual cortex by three parallel
physiologically defined pathways, that is, parvo-, magno-, and
koniocellular. These neural pathways may underlie the detec-
tion mechanisms defined psychophysically.8,9 The parvocellu-
lar pathway is thought to underlie fine discrimination of visual
features, particularly in the central visual field, and is sensitive
to modulation of long-wavelength (L) and middle-wavelength
(M) cone contrast, which results in red–green chromatic con-
trast.10 In addition, the parvocellular channel also responds to
achromatic stimulation with high spatial and low temporal
frequencies.11 On the other hand, the magnocellular pathway
is most sensitive to achromatic stimuli with low spatial and
high temporal frequencies. The magnocellular pathway is
thought to play an important role in spatial localization and
motion processing.12 The function of the koniocellular path-
way is less understood.13 It most certainly plays a role in color
vision due to its sensitivity to short-wavelength (S) cone (blue–
yellow) contrast. In addition, it might be involved in spatial
processing, as suggested by its significant response to periph-
eral stimulation,14,15 and in motion perception.16,17 Thus, spe-
cific deficits in each of these independent pathways might
have specific implications in the visual profile of these patients
and, thus, it is important that we understand the origin of the
visual impairments investigated.
With this in mind, we tested contrast sensitivity in children
and adolescents with NF1 and adults with NF1 using low-level
visual stimulation that preferentially activate the red–green
(parvocellular), blue–yellow (koniocellular), or low spatial
high temporal frequency (strongly magnocellular biased) chan-
nels. In addition, we also tested a parvocellular-biased achro-
matic channel (stimuli with higher spatial and lower temporal
frequency). Furthermore, we studied if the dependence of
contrast sensitivity on eccentricity was altered. Parvo- and
magnocellular pathways differ in the way their responses de-
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pend on the eccentricity of the visual stimuli, with the mag-
nocellular pathway dominating at more peripheral locations.18
Thus, impairments of these pathways in central or peripheral
locations could have different behavioral consequences that
should be considered.
METHODS
Participants: Recruitment and Exclusion Criteria
Thirty-five families with NF1 were recruited in collaboration with the
Genetics Department of the Pediatric Hospital of Coimbra in Portugal.
All participants met the National Institutes of Health Consensus
Development Conference clinical criteria for NF1.19 We excluded
patients with known brain pathology or ophthalmological problems
that could influence the results. Furthermore, to ensure that the
patients included in the study had no unknown brain pathology
(e.g., optic gliomas), they were submitted to magnetic resonance
structural scans (MP-RAGE [magnetization-prepared rapid gradient-
echo] and FLAIR [fluid-attenuated inversion recovery] sequences).
Standard neuroradiological assessments were carried out by an
experienced neuroradiologist. Significant structural anomalies, be-
sides T2-hyperintensities, were identified in four individuals with
NF1. These were excluded from this study.
In addition, all patients with NF1 were submitted to a complete
ophthalmic examination, including best-corrected visual acuity, stere-
opsis evaluation (Randot Stereotest; Stereo Optical Co., Chicago, IL),
slit-lamp examination of anterior chamber structures, and fundus ex-
amination. Lisch nodules were observed in 55% of patients but no
anomalies that could affect vision were found.
For the control group, we recruited unaffected siblings (n 3) and
parents and spouses of patients with NF1 (n  7). Additional healthy
children and adolescents were recruited from a school with wide
socioeconomic coverage (n  30), whereas additional healthy adults
were recruited from an adult further education center. These typically
developing participants had no history of learning, developmental,
cognitive, neurologic, or neuropsychiatric problems.
Thus, for analysis, we included 19 children and adolescents with
NF1 and 33 control children and adolescents. In the adult groups, we
included 12 individuals with NF1 and 23 controls. There were no
statistical differences for age and education level between the NF1 and
control groups. Furthermore, there were no significant differences
between ages of female participants of NF1 and control groups. The
same was true for male participants. Furthermore, sex ratios were
similar in both groups. Characteristics of participants are summarized
in Table 1.
Parents of children on stimulant medication (methylphenidate)
were requested not to give the medication on the days of testing (three
children with NF1), ensuring that these children were not under the
influence of methylphenidate during testing.
Protocol Approvals and Patient Consents
The study was conducted in accordance with the tenets of the Decla-
ration of Helsinki and was approved by the Ethics Committees of the
Faculty of Medicine of Coimbra and of the Children’s Hospital of
Coimbra. Written informed consent was obtained from participants
older than 17 years of age and from the legal representative in the case
of participants younger than 18 years of age, after explanation of the
nature and possible consequences of the study. Children and adoles-
cents younger than 18 years of age gave written or oral informed
consent.
Genetic Characterization of Participants with NF1
To further characterize our NF1 population, patients’ DNA was ex-
tracted from peripheral blood using standard procedures, and whole
gene sequencing and multiplex ligation-dependent probe amplification
analysis were carried out with the aim of identifying the disease
causing NF1 mutations20 (see Results section).
Neuropsychological Characterization
of Participants
In all participants with NF1 younger than 17 years of age (n  18) and
in a subgroup of control children and adolescents (n  18), we
administered the Portuguese adapted version of the Wechsler Intelli-
gence Scale for Children (WISC-III).21 For participants older than 17
years of age, we applied the 12-item short form of the Raven Advanced
Progressive Matrices22 as an indication of nonverbal intelligence. Par-
ticipants also performed Benton’s Facial Recognition Test (FRT)23 and
Benton’s Judgment of Line Orientation (JLO) (Form H).24 Two adult
control participants and one child with NF1 did not perform the FRT
and JLO tests.
Adults performed all tests (contrast sensitivity, nonverbal intelli-
gence, visuospatial, and visuoperceptual tests) on the same day with
testing duration of approximately 1.75 hours, including breaks. Chil-
TABLE 1. Characteristics of NF1 and Control Groups
Factor
Children and Adolescents Adults
NF1 Controls P NF1 Controls P
Age, y
Mean  SD 11.5  2.5 11.7  2.3 0.74 33.3  4.1 34.8  5.8 0.43
Range 7–17 7–16 26–38 26–45
Sex ratio
% Female 63% 61% 0.86 92% 91% 0.97
Education level, y
Mean  SD — — 8.4  3.8 10.4  4.3 0.19
Range 4–16 4–17
Full-scale IQ (WISC-III)
Mean  SD 96  15 111  15 0.01 — —
Raven score
Mean  SD — — 6.7  2.7 8.3  2.9 0.12
Benton’s JLO
Mean  SD 17.5  6.1 24.0  4.2 0.01 19.3  4.1 22.8  5.7 0.07
Benton’s FRT
Mean  SD 20.1  2.1 21.6  2.3 0.05 22.3  1.8 23.2  1.9 0.21
P values were relative to t-test comparisons between NF1 and control groups, except for comparisons
of sex ratio where chi-square tests were used, and comparisons of JLO scores where the Mann-Whitney
test was used.
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dren and adolescents performed all tests except the WISC-III that was
performed on a subsequent visit to the institute.
The neuropsychological characterization of the groups is summa-
rized in Table 1. As expected, full-scale IQ of children and adolescents
with NF1 was significantly lower than full-scale IQ of controls (P 
0.01). For the adult groups, although the NF1 Raven scores showed a
tendency to be lower than control levels, this difference was not
significant. Furthermore, the performance on the JLO test was signifi-
cantly impaired in the children and adolescent groups (P  0.001).
Also, in the adult groups, these scores were lower in the NF1 group,
but the difference did not reach significance (P  0.07). Interestingly,
children and adolescents with NF1 were significantly impaired on the
FRT (P  0.05), suggesting impaired visuoperceptual abilities. How-
ever, we did not find a significant difference for the adults’ perfor-
mance on this test.
Achromatic Contrast Sensitivity Test for Low
Temporal and Higher Spatial Frequency Channel
This contrast sensitivity test used static achromatic vertical gratings,
with an intermediate spatiotemporal profile aimed at biasing the acti-
vation of the parvocellular pathway (for more specific modulation of
this pathway, see the following text on chromatic tests). This task was
based on a custom-made task described before.18 Stimuli were static
vertical gratings, with a spatial frequency of 3.5 cycles per degree
(mean background luminance of 51 cd/m2), displayed on a 21-inch
monitor (Trinitron GDM–F520 Sony monitor). The stimulus sizes,
shapes, and locations are represented in Figure 1A. The width of each
stimulus was 10 ° of visual angle (35 grating cycles). Stimulus duration
was 200 ms and the interstimulus interval varied randomly between
2300 and 2800 ms. The stimuli were presented with no temporal filter
pseudorandomly within nine locations of the visual field (Fig. 1A).
Participants were positioned comfortably at a viewing distance of 36
cm and were instructed to fixate the black square in the center of the
screen and report the presence of “striped” targets (detection task) in
any of the nine locations by means of a button press. A chin and
forehead rest was used to ensure a stable viewing position throughout
testing. Participants’ reliability was evaluated by the inclusion of false-
positive (0% contrast stimuli) and false-negative (100% contrast) “catch
trials.” Trials with false positives or false negatives 33% were aborted
or, if run until the end, excluded from analysis, according to standard
criteria. The trial was then repeated after a small rest period. If in
repeated trials the participant still responded with a high number of
false positives or false negatives, then all data from that participant
were not used in analysis.
During task performance the experimenter visually monitored each
participant’s fixation. If the participant was not able to maintain fixa-
tion the test was aborted and a second trial was run after repetition of
test instructions.
This task was performed in a monocular way for both eyes, with
the first tested eye being chosen in a random manner and an opaque
patch occluding the other eye.
Luminance contrast of the stimulus was expressed according to
Michelson. Contrast sensitivity results were expressed in terms of
decibel (dB) units, dB  20  log (1/c), with contrast c measured as a
percentage. To obtain the psychophysical thresholds, the test uses
nine randomly interleaved logarithmic staircases, one for each location
tested. The contrast value used for a given trial was calculated using
the previous trial value plus or minus the step size in dB. The initial
step size used was 3 dB. Staircases were run for a total of four reversals,
with the contrast at the final two reversals being averaged to estimate
the contrast threshold.
For analysis, we averaged the contrast sensitivity values of each
visual field location of both eyes for each individual. Furthermore, to
study the effect of eccentricity, we calculated the average contrast
sensitivity of three zones: 0–5, the central location with eccentricity
between 0 and 5° of visual angle (light gray circular region in Fig. 1A);
5–10, averaged contrast sensitivity levels of the four locations with
A
B
10º
visual angle
10º
visual angle
C
FIGURE 1. Schematic representation of the contrast sensitivity tests used.
(A) Schematic representation of the sizes and shapes of the nine locations
within the visual field where the stimuli used in the achromatic contrast
sensitivity test for low temporal and higher spatial frequency channel were
presented. The black square in themiddle of the figure represents the fixation
square. (B) Schematic illustration of the stimuli used in the chromatic sensi-
tivity tests (Cambridge Color Test) representing a luminance noise stimulus
with superimposed chromatic target (Landolt C shape, colored in red). (C)
Schematic representation of the sizes and shapes of 17 locations within the
visual field where the stimuli used in the achromatic contrast sensitivity test
for high temporal and low spatial frequency channel (magnocellular) were
presented. The two nasal locations are not shown. The black square in the
middle of the figure represents the fixation square.
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eccentricity between 5 and 10° (four gray regions adjacent to circular
region in Fig. 1A); and 10–20, averaged contrast sensitivity levels of the
four outermost locations (eccentricity between 10 and 20°; four darker
gray squares in Fig. 1A).
Chromatic Sensitivity Tests
We probed chromatic contrast sensitivities using a standard commer-
cial color vision test (Cambridge Color Test [CCT]; Cambridge Re-
search Systems, Rochester, UK), a computer-controlled psychophysical
method.25 Stimuli were displayed on a 21-inch monitor (GDM-F520;
Sony, Tokyo, Japan). Participants viewed a static pattern of circles of
various sizes and luminances with superimposed chromatic contrast
defining a C (gap size: 1.6°; outer diameter: 7.6°; inner diameter: 3.81°;
viewing distance: 1.8 m; Fig. 1B) and were instructed to indicate
whether the gap was facing up, down, left, or right, by pressing one of
four buttons. A chin and forehead rest was used to ensure a stable
viewing position throughout testing. We used a color version of the
test (Trivector; CCT), where the targets differ from the background
along one of the three color confusion lines: protan, deutan, and tritan.
The test uses three randomly interleaved staircases to dynamically
adjust the chromaticity of the target according to the participant’s
performance to establish the chromaticity difference between target
and background needed for reliable report of the orientation of the C.
Occasional control trials, with a target presented at maximal chromatic
saturation, were introduced to ensure that the participant was alert.
Testing on any one staircase was terminated after 11 reversals and the
mean of the last 6 reversals was taken as the threshold estimate for the
direction being tested.
The test was performed in a monocular way, with the eye tested
first chosen in a random manner and an opaque patch occluding the
other eye. An initial session of training ensured all participants under-
stood the task.
The chromatic contrast along each of three color confusion lines,
protan, deutan, and tritan, activates only one type of cone photore-
ceptors. Colors within the protan line activate the L-cone type, within
deutan activate the M-cone type, and within the tritan line activate the
S-cone type. We took as the threshold for the red–green (parvocellu-
lar) chromatic channel the average of the thresholds along protan and
deutan lines and the threshold along the tritan line as the blue–yellow
(koniocellular) contrast threshold. Note that high chromatic thresholds
relate to low-contrast sensitivity.
Achromatic Contrast Sensitivity Test for High
Temporal and Low Spatial Frequency
Channel (Magnocellular)
Magnocellular contrast sensitivity was measured using a commercially
available system (Humphrey Matrix perimeter, Welch Allyn, Skaneate-
les, NY; Zeiss Humphrey Systems, Dublin, CA). Stimuli were sinusoidal
vertical gratings with high temporal frequency (25 Hz) and low spatial
frequency (0.25 cycles per degree) frequency-doubling stimuli. We
used a strategy (N-30-F) that tests a total of 19 locations (four 10°
square targets per quadrant and a central 10° diameter circular target
plus two nasal locations; Fig. 1C). During testing, stimuli were pre-
sented successively with each of the 19 target locations selected on a
random basis. Each stimulus was presented for a maximum of 720 ms.
During the first 160 ms, stimulus contrast was increased gradually from
zero to the contrast selected for that trial. If the stimulus was not seen,
it remained at that contrast for up to 400 ms and was then gradually
decreased to zero during the final 160 ms. Between stimulus presen-
tations, there was an interval of up to 500 ms, with duration randomly
defined. This test uses a staircase threshold strategy known as Modified
Binary Search, with a four-reversals rule for determining the threshold
level and a dynamic luminance ratio range from 56 to 0 dB.
The instrument has a sliding visor that automatically occludes one
of the eyes, allowing monocular viewing. The first eye tested was
chosen in a random manner. Participants were instructed to rest their
forehead on the visor and fixate the black square in the center of the
screen and report the presence of “striped” targets. Furthermore, a
brief practice trial ensured that the participant understood the task.
During testing, the experimenter visually monitored fixation, by at-
tending the image of the participant’s eye displayed on the experi-
menter screen. The test was aborted if the participant was not able to
maintain fixation. Furthermore, if necessary, the test was paused to
allow the participant to rest. In addition, performance reliability was
assessed by monitoring fixation loss using stimuli placed on the blind
spot and by computing false positive and negative errors. Tests with
false positives, false negatives, or fixation losses  33% were aborted
or, if run until the end, excluded from analysis, according to standard
criteria. The trial was then repeated after a small rest period. If in
repeated trials the participant still responded with a high number of
errors, then all data from that participant were not used in the analysis.
This frequency-doubling perimetry has been shown to reveal a
significant difference between the first eye tested compared with the
second eye tested.26 Therefore, we analyzed our data comparing the
first eye with the second eye tested. This eye order effect is due to
monocular light adaptation and appears when the second eye is tested
shortly after the first one. In participants where testing of one of the
eyes had to be repeated (due to a high number of false positives, false
negatives, or fixation errors) this sequence was disrupted, thereby
changing the eyes’ state of adaptation. This difference in timings
between eye tests might interfere with contrast sensitivity levels. Thus,
we chose to analyze data only from the participants that performed
successfully the tests of one eye after the other without repetitions.
After excluding these participants, we remained with 16 children and
adolescents with NF1, 30 control children and adolescents, and 10
adults with NF1 and 20 control adults. As expected, we found a
significant order effect of the eye tested [F(1,72)  15.9, P  0.001],
with the average contrast sensitivity of the second eye significantly
lower than the sensitivity of the first eye. No significant interaction was
found between eye and clinical group or between eye and age group.
These findings indicated that the effect of eye order testing was the
same for controls and participants with NF1. Thus, for each partici-
pant, we averaged the contrast sensitivity of both eyes, for each visual
field location.
To study the effect of eccentricity, we averaged the levels of
contrast sensitivity in three zones: 0 to 5 (the central location with
eccentricity between 0 and 5° of visual angle; light gray circular region
in Fig. 1C); 5 to 10 (4 locations with eccentricity between 5 and 10°;
4 gray regions adjacent to circular region in Fig. 1C); and 10 to 20 (12
locations with eccentricity between 10 and 20°; darker gray squares in
Fig. 1C).
Statistical Analysis
All statistical analyses were performed with a commercial statistics/
analytical program (PAWS Statistics 18; SPSS Inc., Chicago, IL). We
verified the normality assumption for the different parameters using
the Shapiro–Wilk test. All measures were normally distributed except
the chromatic thresholds and the scores from the JLO test. For the
normally distributed data, we used repeated-measures ANOVA analy-
ses, parametric t-tests, and Pearson’s correlation analyses. For the
nonnormally distributed data, we used the Mann–Whitney test and
Spearman’s correlation analyses.
RESULTS
Genetic Characterization of the Individuals
with NF1
In our cohort of patients with NF1, we identified 23 different
NF1 mutations in 24 families. NF1 mutations were therefore
identified in 69% of the families, confirming the NF1 diagnosis
of the majority of the recruited patients with NF1. This per-
centage of mutation identification is in line with previous
studies27 (Table 228–34). One of the nonsense mutations was
found in two unrelated families. Two missense mutations re-
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ported in this study represent novel changes within the gene.
None of these sequence changes has been identified in 1000
normal chromosomes studied for entire NF1 gene mutations.
All these sequence changes are evolutionarily conserved in
different species.
Achromatic Contrast Sensitivity at an
Intermediate Spatiotemporal Frequency Channel
We measured the achromatic contrast sensitivity (with a par-
vocellular bias) for nine visual field locations in individuals
with NF1 and control participants. Using repeated-measures
analyses, we studied the effect of eccentricity, clinical group,
and age group. We found a highly significant effect of clinical
group [F(1,83)  36.1, P  0.001; Fig. 2] with no effect of age
group (children/adolescents and adults) or interaction be-
tween clinical group and age group, indicating that the con-
trast sensitivity deficit was present in both children and ado-
lescents with NF1 and adults with NF1. Furthermore, as
expected, we found a significant effect of eccentricity
[F(1.7,137) 444, P 0.001; Fig. 2] and a significant interaction
between eccentricity and clinical group [F(1.7,137)  4.8, P 
0.05], with the control group showing a greater decline of
contrast sensitivity with eccentricity than that of the NF1
group (Fig. 2). In addition, we also found a significant interac-
tion between eccentricity and age group [F(1.7,137)  9.6, P 
0.001], with the adult participants showing a higher effect of
eccentricity than that of the children and adolescents group,
but no interaction between eccentricity, clinical group, and
age group. Although there was an interaction between eccen-
tricity and clinical group, the contrast sensitivity values of
individuals with NF1 were always significantly lower than
control levels for all eccentricities tested (post hoc t-tests: P 
0.001; Fig. 2).
Chromatic Contrast Sensitivity
Interestingly, we found that, as for the achromatic parvocellu-
lar sensitivity, chromatic parvocellular thresholds were signif-
icantly affected in individuals with NF1 (thresholds in CIE
[International Commission on Illumination] 1976 L*, u*, v*
color space units, median [interquartile range, Q1–Q3]: con-
trol  0.0051 [0.0042–0.0062]; NF1  0.0061 [0.0055–
0.0070]; nonparametric test, P  0.01). This difference was
significant both for children and adolescents (P 0.05) and for
adults (P  0.05), separately. In contrast, the koniocellular
thresholds were not significantly different between the groups
(median [interquartile range, Q1–Q3]: control  0.0075
[0.0060–0.0098]; NF1  0.0084 [0.0071–0.0100]; n.s.).
TABLE 2. Summary of the Disease Causing NF1 Mutations Identified in 24 Families with NF1
Participating in This Study
Mutation Type
Mutation at Coding DNA
Level
Mutation at Protein
Level Reference
Nonsense c.2041CT p.Arg681X Ars et al.28
c.2446CT p.Arg816X Maynard et al.29
c.3318CG p.Tyr1109X Not previously reported
c.3942GA p.Trp1314X Upadhyaya et al.30
c.4537CT p.Arg1515X Not previously reported
c.5458CT p.Gln1828X Not previously reported
c.574CT p.Arg192X Toliat et al.31
Frameshift c.5565_5566 CTdel p.Asn1963fsX8 Not previously reported
C7206CAdel p.His2402GlnfX3 Not previously reported
c.1329 del T Not previously reported
c.del4815_4827 del p.His1605X Not previously reported
TGTCTTACTGACT
c.2500–2501 ins C Not previously reported
Missense c.2084TC p.Leu695Pro Fahsold et al.32
c.2786TC p.Leu929Pro Not previously reported
c.3827GC p.Arg1276Gln Fahsold et al.32
c.5587TC p.Phe1863Leu Not previously reported
c.1466AG p.Tyr489Cys Osborn and Upadhyaya33
Splice site c.7301GA IVS5 Not previously reported
c.17203AG IVS 11 Purandare et al.34
c.3196–2AC IVS 19a Not previously reported
c.5944–6AG IVS31 Not previously reported
c.80971GA IVS 47 Not previously reported
Gross deletion Exons 4A, 4B Not previously reported
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FIGURE 2. Individuals with NF1 showed decreased contrast sensitiv-
ity at an intermediate spatiotemporal frequency channel (parvocellular-
biased). The graph shows contrast sensitivity versus eccentricity in
both control participants and individuals with NF1. Contrast sensitiv-
ities at eccentricities 0–5°, 5–10°, and 10–20° were calculated as the
average of the sensitivities of the central locations of both eyes, of the
four locations with eccentricity between 5 and 10° of both eyes and of
the 4 locations with eccentricity between 10 and 20° of both eyes,
respectively. All data are expressed as mean  SE. ***P  0.001.
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Magnocellular-Biased Contrast Sensitivity
In addition, we studied the effect of eccentricity, clinical
group, and age group in magnocellular-biased contrast sensi-
tivity. Repeated-measures analysis revealed a significant effect
of clinical group [F(1,72)  8.0, P  0.01; Fig. 3], no effect of
age group, and no interaction between clinical group and age
group. These results indicated a magnocellular-biased contrast
sensitivity deficit present in both children and adolescents with
NF1 and adults with NF1. Furthermore, we found a significant
effect of eccentricity [F(1.8,144)  43.5, P  0.001; Fig. 3], a
significant interaction between eccentricity and clinical group
[F(1.8,144)  3.7, P  0.05] and no interaction between eccen-
tricity and age group or between eccentricity, age group, and
clinical group. The interaction between eccentricity and clin-
ical group was associated with a steeper decline in contrast
sensitivity with eccentricity in the NF1 group than that of the
control group (Fig. 3). In fact, post hoc t-tests showed that the
contrast sensitivity in the central location of the visual field was
not significantly different between the clinical groups and only
the more peripheral locations, from 5° eccentricity onward,
presented significant contrast sensitivity deficits (P  0.05).
Relation between NF1 Low-Level Visual Deficits
and Cognitive Abilities
NF1 contrast sensitivity values did not correlate with the indi-
vidual neuropsychological data, that is, IQ (measured as full-
scale IQ, for children and adolescents, and Raven scores, for
adults), visuospatial skills (measured using the Benton’s JLO
test), and visuoperceptual skills (measured using the Benton’s
FRT). This lack of correlation suggests that the contrast sensi-
tivity impairments found in NF1 are not explained by low
intellectual abilities or deficits in visuospatial or visuopercep-
tual skills.
DISCUSSION
In this study, we described, for the first time, the presence of
low-level visual contrast sensitivity deficits in individuals with
NF1 in the absence of signs of structural brain damage.
The contrast sensitivity tasks used were chosen to bias
activation of each of the three retinocortical pathways (parvo-,
konio-, and magnocellular), with their different physiologic
properties, although not completely isolating the function of
each pathway.10 The intermediate spatial/low temporal fre-
quency test and the chromatic red–green test activate mostly
the parvocellular pathway. The low spatial/high temporal fre-
quency test activates mostly the magnocellular pathway and
the chromatic blue–yellow test activates mostly the koniocel-
lular channel. Thus, our results suggest that individuals with
NF1 present a pronounced parvocellular central and peripheral
sensitivity deficit, impaired peripheral magnocellular sensitiv-
ity, and relatively spared central magno- and koniocellular
function. The peripheral pattern of magnocellular impairment
has relevant functional implications, given the dominance of
this channel in peripheral vision and in terms of input to the
dorsal stream, more specialized in motion detection and object
localization.12
One of the main hypotheses explaining the pathophysio-
logic mechanism underlying the cognitive deficits observed in
this disease indicates enhanced inhibitory neurotransmission.
However, this hypothesis was tested only in NF1 mice mod-
els.35–37 Interestingly, our study, in humans, identified a pat-
tern of visual impairments, deficient parvocellular contrast
sensitivity, and relatively spared central magnocellular sensitiv-
ity, also observed in studies investigating the effect of benzo-
diazepines, drugs that enhance GABAergic (inhibitory) neu-
rotransmission, in humans.38,39 Thus, our results are in line
with the impaired inhibition hypothesis and might be of im-
portance, given that they provide evidence that an indirect
visual marker of inhibition (contrast sensitivity) is altered in
this condition. The understanding of the nature of the neuro-
physiologic and psychophysical anomalies present in NF1 is
important for the development of pharmacologic therapies
targeting the cognitive impairments of these patients. There-
fore, we believe that our study provides important evidence
that helps predict the effects of drug therapies in these pa-
tients. We should note, nevertheless, that alternative causes for
this contrast sensitivity deficit are possible. We do believe that
future studies should directly address this question.
Contrast sensitivity has been shown to increase during
childhood and adolescence, reaching adult levels in the late
teens.40,41 However, in our study, we did not find an effect of
age group. We believe that the lack of an age group effect
might be because, although contrast sensitivity increases with
age for children and adolescents, it declines with age for
adults.41,42 This inverted U shape of contrast sensitivity would
result in no difference between the contrast sensitivity of
group averages. Interestingly, the lack of an age effect in our
data also suggests that the NF1 deficits in contrast sensitivity
found in children and adolescents persist into adulthood.
Low-level visual deficits could underlie, at least in part, the
NF1 cognitive impairments. However, we observed no corre-
lation between contrast sensitivity, intelligence, visuospatial,
and visuoperceptual abilities, suggesting that these deficits
have independent causes. This observation is in line with our
previous results in another neurodevelopmental model, Wil-
liams Syndrome.43 Individuals with NF1, like individuals with
Williams Syndrome, are impaired in visuospatial processing,3,44
suggesting a dorsal stream deficit that could be the conse-
quence of impaired magnocellular input. However, in line with
our observation in Williams Syndrome,43 although we found a
significant decrease in magnocellular sensitivity, these sensitiv-
ity levels did not correlate with visuospatial abilities, measured
with the JLO test, or visuoperceptual abilities, measured with
the Benton’s FRT. Furthermore, the more severely affected
parvocellular contrast sensitivity did not correlate with any of
these neuropsychological tests, indicating that these low-level
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FIGURE 3. Magnocellular-biased contrast sensitivity is affected in in-
dividuals with NF1. The graph shows contrast sensitivity versus eccen-
tricity in both controls and individuals with NF1. Contrast sensitivity at
eccentricities 0–5°, 5–10°, and 10–20° were calculated, respectively,
as the average of the sensitivities of the central locations of both eyes,
of the four locations with eccentricity between 5 and 10° of both eyes
and of the 12 locations with eccentricity between 10 and 20° of both
eyes. All data are expressed as mean  SE. *P  0.05; **P  0.01.
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visual deficits are not the direct cause of these higher-order
impairments.
In conclusion, we observed contrast sensitivity deficits in
individuals with NF1, thereby identifying for the first time
low-level visual impairments in this disorder. Further studies
are needed to identify cognitive domains where deficits could
be explained by decreased contrast sensitivity.
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